Animal studies have not demonstrated any teratogenic effects. In the absence of teratogenic effects in animals, no teratogenic effects are expected in humans. To date, substances causing malformations in humans have been shown to be teratogenic in animals during studies conducted properly in 2 species. In a clinical context, there are no sufficient relevant data yet in order to evaluate the possible teratogenic or fetotoxic effect of Nifuroxazide when administered during pregnancy. Consequently, as precautionary measure, use of Rapiz Capsule should preferably be avoided during pregnancy. Breastfeeding is possible in the event of brief treatment with Rapiz Capsule.